tadalafil / Generic mfg. - LARVOL DELTA

Drug-Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance. (PubMed, Mol Pharm) - "Physical stability of the developed coamorphous system evaluated under accelerated as well as long-term stability conditions indicated reasonable stability for potential drug product usage. Considering its industrial applicability due to obvious benefits, viz., single solid phase, improved solubility, dissolution, and better pharmacokinetic parameters leading to higher bioavailability, the developed coamorphous system could prove to be a better therapeutic alternative over the marketed physical mixture."

Journal • Benign Prostatic Hyperplasia

Spatial and Temporal Tracking of Counterfeit Phosphodiesterase Type V Inhibitors Use Based on Wastewater Analysis. (PubMed, Environ Sci Technol) - "Among the three target compounds, neither tadalafil nor vardenafil was detected in any sample. Sildenafil, however, was found in 94.5% of the samples, with concentrations ranging from below the limit of quantification (LOQ) to 75.4 ng/L...Subpopulation analysis further revealed that college students (38.5 mg/d/1000 inh) and island residents (28.6 mg/d/1000 inh) had lower levels of use compared to the general population (85.1 mg/d/1000 inh). These results highlight the potential of wastewater-based drug surveillance in tracking consumption trends of nonprescribed and counterfeit pharmaceuticals, offering robust evidence to inform regulatory efforts and improve public risk perception."

Journal • Erectile Dysfunction

Do patients Rezum medications?-a real-world analysis of medical retreatment after water vapor thermal therapy. (PubMed, Transl Androl Urol) - "Alpha blockers were the most commonly restarted medication (40.5%), followed by daily tadalafil (25.5%) and 5-alpha reductase inhibitors (10.6%); 23.4% of patients restarted multiple medications...Nearly one-third of patients undergo medical retreatment after WVTT, often within the first year. Early symptom trajectory, preoperative medication use, and close follow-up may help identify patients at risk and improve long-term outcomes."

Journal • Real-world evidence • Benign Prostatic Hyperplasia

Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. (PubMed, Int J Surg) - "Silodosin is highly effective for BPH-LUTS, particularly for voiding symptoms, but carries a elevated risk of ejaculatory dysfunction. Combination with tadalafil may enhance urinary flow. Clinicians should weigh efficacy against adverse events; further trials are needed to confirm long-term benefits."

Journal • Retrospective data • Benign Prostatic Hyperplasia

PDE-5 inhibitors in complex matrices: Recent updates on pretreatment and detection methods. (PubMed, J Chromatogr A) - "Common medications include sildenafil, tadalafil, and vardenafil. Among these, the use of high-resolution mass spectrometry is a current research hotspot. The review critically evaluates the advantages and limitations of existing methodologies, identifies future development directions, and supports the selection of efficient analytical strategies for specific sample matrices and research purposes."

Journal • Review • Erectile Dysfunction

Bioequivalence Study of Tadalafil Oral Soluble Film and Tadalafil Tablet in Healthy Chinese Volunteers Under Fasting Conditions. (PubMed, Clin Transl Sci) - "All investigational formulations were well tolerated in the study. Trial Registration: chinadrugtrials.org.cn (CTR20181044)."

Clinical • Journal

Cognitive outcomes after tadalafil treatment in patients with cerebral small vessel disease: ETLAS-2 sub-study. (PubMed, Cereb Circ Cogn Behav) - P2 | "A longer treatment time may be required to identify potential effects on cognitive outcomes, which could be secondary to improved blood flow. URL: https://www.clinicaltrials.gov, Unique identifier: NCT05173896."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia

Isolated trigeminal sensory neuropathy in a patient with mixed connective tissue disease: A diagnostic challenge (EHF-EHC 2025) - "Chronic medication included gabapentin 100mg three times daily, prednisolone 10mg, hydroxychloroquine 400mg, aspirin 150mg, pentoxifylline 400mg, nifedipine 20mg, furosemide, tadalafil and ambrisentan. This case highlights the importance of considering autoimmune mechanisms in isolated trigeminal neuropathies, especially in patients with systemic connective tissue disease. EMG may assist in detecting trigeminal dysfunction, and intrathecal autoantibodies, even without structural lesions, support an immune-mediated process and underscore the value of CSF analysis in atypical neurological presentations."

Clinical • Cardiovascular • Immunology • Melanoma • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Solid Tumor

A Systematic Literature Review Exploring the Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension. (PubMed, Pulm Circ) - "Two studies reported patients who switched from sildenafil to tadalafil treatment, treatment transition was feasible. Although comparable when used as monotherapy, this qualitative analysis suggests that tadalafil + ERA combination therapy may have more favorable 6MWD improvements than sildenafil + ERA combination therapy."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Comprehensive Analytical Studies on the Solubility and Dissolution Rate Enhancement of Tadalafil with Type IV Lipid Formulations. (PubMed, Pharmaceutics) - "Cytotoxicity evaluation using the MTT assay in Caco-2 cells confirmed the biocompatibility of both drug-free and TDL-loaded formulations, with IC50 values of 19.55 µg/mL and 17.55 µg/mL, respectively. The overall results suggested that the developed solid Type IV lipid formulations can improve the dissolution rate of TDL, which would potentially lead to an improvement in its oral bioavailability and, consequently, a reduction in the treatment dose as a safe delivery system."

Journal

Evaluation of tadalafil in combination with Low-Intensity Pulsed Ultrasound (LIPUS) for erectile dysfunction: a protocol for a randomized controlled trial (SPIRIT Compliant). (PubMed, Trials) - P=N/A | "The study aims to evaluate the efficacy of tadalafil combined with LIPUS for treating ED and to improve the evaluation of treatment response in erectile dysfunction by integrating blood flow parameters and two-dimensional shear wave elastography."

Journal • Erectile Dysfunction • Inflammation

N-Homocysteinylation of HMGB1/2 Promotes Corpus Cavernosum Endothelial Senescence in Erectile Dysfunction. (PubMed, Int J Biol Sci) - "Competitive inhibition of MARS1 with N-acetylcysteine (NAC) attenuates endothelial senescence and improves erectile function in middle-aged individuals with hyperhomocysteinemia by reducing HTL, rather than Hcy itself, while synergizing with tadalafil. Collectively, our findings highlight the pivotal role of the age-dependent MARS1-HTL axis in the pathogenesis of homocysteine-induced ED, offering a promising therapeutic strategy for ED in the aging population."

Journal • Erectile Dysfunction • Metabolic Disorders • HMGB1

The Missing Lung: A 33-Year-Old's Battle with Congenital Agenesis and Cor Pulmonale (APSR 2025) - "Treated with LTOT, diuretics, tadalafil (20 mg/day), and ambrisentan (5 mg/day), he showed partial improvement at 3 months (SpO 2 94% on 2L O 2 , PASP 87 mmHg), though RV dysfunction persisted. Management focuses on oxygen therapy, diuretics, and targeted vasodilators (e.g., PDE-5 inhibitors), with lung transplantation considered in advanced cases. This case underscores the need for early multidisciplinary intervention to mitigate PH progression and improve outcomes in adult survivors of congenital lung agenesis."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Infectious Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Integrating machine learning with lateral flow immunoassay for ultrafast and sensitive tadalafil detection. (PubMed, Food Chem) - "The assay exhibited a strong correlation with LC-MS/MS, with recoveries ranging from 92.3 % to 112 % (coefficient variations ≤15.37 %). The LFIA@ML showcased the ability to reduce detection time by using the Random Forest algorithm and was validated in wine samples."

Journal

Tadalafil protects against renal fibrosis after ischemia-reperfusion injury by inhibiting Akt/NF-κB signaling pathway. (PubMed, Eur J Pharmacol) - "Mechanistically, Tadalafil was found to inhibit the activation of the Protein Kinase B (Akt)/Nuclear Factor kappa-B (NF-κB) signaling pathway, thereby exerting its therapeutic effects on renal fibrosis. These findings confirm that Tadalafil protects against ischemia-reperfusion-induced renal injury by inhibiting mesangial cell activation and modulating the Akt/NF-κB pathway, supporting the potential of phosphodiesterase 5 inhibitors as a novel therapeutic option for renal fibrosis."

Journal • Cardiovascular • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • Reperfusion Injury

Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH). (PubMed, Fr J Urol) - "These recommendations provide urologists with evidence-based guidance for more personalized management of BPH-related LUTS."

Clinical guideline • Journal • Review • Benign Prostatic Hyperplasia • Erectile Dysfunction

ASP-011-SIL: Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Aspargo Labs, Inc

New P2 trial • Erectile Dysfunction

Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database. (PubMed, Eur Urol Focus) - "PDE5i usage is associated with distinct efficacy and AE profiles in a large real-world dataset guiding treatment recommendations for urologists. Future DTC data might be used to complement clinical trial data."

Head-to-Head • Journal • Erectile Dysfunction

Macitentan Plus Tadalafil Single-Tablet Combination Therapy in Chinese Patients With Pulmonary Arterial Hypertension: A Subgroup Analysis of the A DUE Study. (PubMed, Pulm Circ) - P3 | "Our findings support the use of M/T STCT for PAH in China. Trial registration: ClinicalTrials.gov https://clinicaltrials.gov/ NCT03904693 (April 5, 2019)."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Sotatercept-Enhanced Quadruple Therapy Reverses Hemodynamic Decline in Severe Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension (AHA 2025) - "Treatment included high-dose corticosteroids, mycophenolate mofetil, rituximab, tadalafil, macitentan, and continuous epoprostenol infusion. This case demonstrates that a proactive, multidisciplinary approach incorporating novel therapies such as sotatercept can reverse the trajectory of life-threatening SLE-PAH. Timely diagnosis, aggressive immunosuppression, and layered vasodilator regimens can restore cardiopulmonary function and delay or avoid transplantation in patients with advanced disease."

Cardiovascular • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pulmonary Arterial Hypertension • Respiratory Diseases • Systemic Lupus Erythematosus

Case report: Successful use of sotatercept to treat pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia. (PubMed, Respir Med Case Rep) - "Despite long-term treatment with epoprostenol, treprostinil, macitentan, and tadalafil, her condition progressed, leading to evaluation for lung transplantation. This is the first reported case of sotatercept use in HHT-associated PAH, highlighting its potential efficacy but also the need for careful monitoring due to increased bleeding risk. Further studies are required to establish the safety and efficacy of sotatercept in this population."

Journal • Cardiovascular • Heart Failure • Hematological Disorders • Hypertension • Otorhinolaryngology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation • TGFB1

Cutting Costs, Not Care: New Models for Affordable Men's Health Medications. (PubMed, Urology) - "CPDC provides significant cost savings on men's health medications compared to Medicare and GoodRx."

Journal • Benign Prostatic Hyperplasia • Erectile Dysfunction • Infertility • Sexual Disorders

AI-assisted identification of a novel vardenafil analog (KD-027) adulterated in capsules. (PubMed, J Forensic Sci) - "However, the increased demand for pharmacological treatments, such as sildenafil, tadalafil, and vardenafil has led to the emergence of counterfeit drugs, posing a serious public health concern. In addition, evidence of coexisting E/Z tautomerism of KD-027 was observed in the NMR data. To the best of our knowledge, this is the first report to identify KD-027 in sexual enhancement products, providing its characteristic mass spectral fragments and NMR data, and demonstrating the utility of ChatGPT-4o in forensic investigations."

Journal • Sexual Disorders

Randomized Controlled Double Blind Feasibility Trial of Tadalafil with Hydroxyurea Versus Hydroxyurea with Placebo for Secondary Prevention of Recurrent Priapism in Men with Sickle Cell Anemia: Pin Trial Final Results (ASH 2023) - P2 | "Our phase 2 trial's primary outcome results (recruitment, retention, and adherence rates) strongly support the feasibility of conducting a definitive phase RCT phase 3 trial for secondary priapism prevention in a low-resource setting where 50% of the global SCA births are located. Although not the primary intent of the phase 2 trial, we did not provide evidence that tadalafil with hydroxyurea was superior to hydroxyurea alone for secondary priapism prevention. We will continue to recommend a fixed dose of 20 mg/kg/day hydroxyurea therapy for secondary priapism prevention."

Clinical • Anemia • Genetic Disorders • Hematological Disorders • Sexual Disorders • Sickle Cell Disease

Radiation Nephritis Associated with Lutetium-177 Prostate-Specific Membrane Antigen (KIDNEY WEEK 2025) - "His outpatient medications include tadalafil 5 mg, vibegron 75 mg, testosterone cypionate 0.3 ml every 7 days, ezetimibe 10 mg, rosuvastatin 5 mg and insulin. Nephropathy attributed to binding of the drug to PSMA-like proteins expressed in the tubules leading to retention of beta emitter in the kidneys. Radiation renal injury is typically evident several months after irradiation."

Acute Kidney Injury • Diabetes • Genito-urinary Cancer • Hypertension • Metabolic Disorders • Nephrology • Prostate Cancer • Renal Disease • Solid Tumor